InspireMD Retains KCSA Strategic Communications as Corporate Communications Counsel
NEW YORK and TEL AVIV, Israel, Aug. 1, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, announced today that it has retained KCSA Strategic Communications ("KCSA"), a leading New York-based communications firm, to direct the Company's investor relations and public relations programs.
KCSA will deploy an integrated investor and public relations campaign designed to increase awareness of InspireMD, its proprietary technology – the MGuard™ Coronary Embolic Protection Stent (EPS) – and its business model among the investment community. The communications program will also target the healthcare and medical technology sectors, in addition to outreach to business and trade publications.
Since KCSA's inception more than 43 years ago, the firm has developed a strong reputation for its work representing domestic and international companies across all industries, including medical devices, healthcare services and biotechnology. Todd Fromer and Lewis Goldberg, Managing Partners of KCSA, will lead the communications team and provide strategic counsel on investor relations and media relations matters.
"It is a critical time for us to implement a proactive communications program to effectively reach the media and general investment community in order to highlight the opportunity for our MGuard stent in treating acute coronary syndromes, namely Acute Myocardial Infarction (AMI)," said Alan Milinazzo, Chief Executive Officer of InspireMD, Inc. "We believe the timing of an expanded communications initiative could not be better, as we recently announced the first patient enrolled in our U.S. registration trial for our MGuard Prime EPS and are preparing to announce the highly anticipated 12-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial at the Transcatheter Cardiovascular Therapeutics (TCT) conference in October 2013."
"InspireMD is addressing the unmet needs of the coronary stent market with its proprietary MGuard™ technology," said Todd Fromer, Managing Partner of KCSA Strategic Communications. "The Company's management team and advisory board have expressed a strong commitment to increasing awareness among its core constituents, including the investment community and the media. Based on our successful track record of working with dozens of innovative emerging healthcare companies, we believe KCSA is uniquely qualified to help tell this compelling story. We look forward to providing our complete range of services to support InspireMD's integrated communications initiatives in the healthcare industry."
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MGuard technology to make its products the industry standard for embolic protection stents and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.
InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR.
MGuard EPS is CE Mark approved. It is not approved for sale in the U.S. by the U.S. Food and Drug Administration (FDA) at this time.
About KCSA Strategic Communications
KCSA is a fully-integrated communications agency specializing in public relations, investor relations and marketing with expertise in financial and professional services, technology, healthcare, media, energy and public services companies. Since 1969, the firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The firm's clients are its best references. For more information, please visit www.kcsa.com.
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multi-national companies, (v) product liability claims, (vi) our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Transition Report on Form 10-K/T and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
SOURCE KCSA Strategic Communications